Karen combines clinical care with clinical trial design and translational research. Her main interests include the discovery of predicted biomarkers of response in high risk breast cancer, in particular triple negative and germline BRCA derived tumours; genomic data interpretation; and how this can be translated into clinical benefit. She is actively involved in the execution and data interpretation of the Personalized Breast Cancer Program (PBCP) and the PARTNER/PARTERING clinical trial.
